Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

advantage of their expertise in cancer immunotherapy. The Phase 1 study on VAC2, a potential treatment for advanced non-small cell lung cancer (NSCLC), has yielded promising results. In this study, five out of eight patients experienced immune-related stable disease as their best response. This is a significant finding, as it indicates that the treatment has the potential to stabilize the progre..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 24.
  • textsms

LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

data-ke-size="size16">LianBio, a biotechnology company committed to bringing innovative medicines to patients in China and other major Asian markets, has recently announced a clinical supply agreement with AstraZeneca in China. The purpose of this agreement is to assess the safety and effectiveness of BBP-398, an investigational SHP2 inhibitor, when used in combination with AstraZeneca's osimert..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 13.
  • textsms

Roche’s Tecentriq Improves Survival in Ineligible NSCLC Patients

a professor at UCL, stated that these results are significant because they provide evidence that Tecentriq can be a viable treatment option for NSCLC patients who cannot tolerate platinum-based chemotherapy. Tecentriq is an immune checkpoint inhibitor that works by blocking the PD-L1 protein on cancer cells, allowing the body's immune system to recognize and attack the tumor. It has already been..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 10.
  • textsms

Roche's Tecentriq Improves Survival in NSCLC Patients Ineligible for Platinum Chemo

Roche’s Tecentriq has been shown to improve survival in non-small cell lung cancer (NSCLC) patients who are not eligible for platinum-based doublet chemotherapy, according to data from the Phase III IPSOS trial. The study, led by University College London (UCL) and supported by Roche, revealed its findings in The Lancet. The results showed that patients treated with Tecentriq had a median overal..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 8.
  • textsms